Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38652331 | 1.00 | PKM (0.44) | PKMRIPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL28980523 | 0.85 | P2RX7 (0.43) | PKMP2RX7MAPT | |
| SCHEMBL5009319 | 0.85 | NLRP3 (0.50) | PKMRIPK1L3MBTL1KMT2ANLRP3 | |
| SCHEMBL30262334 | 0.84 | PKM (0.40) | PKML3MBTL1KMT2ATDP1NLRP3 | |
| SCHEMBL29281165 | 0.84 | PKM (0.40) | PKML3MBTL1KMT2ATDP1NLRP3 | |
| SCHEMBL25244752 | 0.83 | PKM (0.42) | PKMKMT2ATDP1NLRP3TSHR | |
| SCHEMBL5151531 | 0.83 | PKM (0.42) | PKML3MBTL1KMT2ATDP1EGFR | |
| SCHEMBL7860050 | 0.83 | CYP4F2 (0.54) | PKMRIPK1NLRP3MAPT | |
| SCHEMBL7253727 | 0.83 | TDP1 (0.41) | PKML3MBTL1KMT2ATDP1NLRP3 | |
| SCHEMBL6445445 | 0.82 | RIPK1 (0.42) | RIPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-A1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| US-7915266-B2 | Promoting microtube polymerization; drug resistant cancer; 5-Azepan-1-yl-7-chloro-6-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyrimidine | WYETH HOLDINGS CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080255157-A1 | 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1684763-B1 | 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES AS ANTICANCER AGENT | WYETH CORP (US) | 2008-06-18 | — | — | EP | disclosed |
| US-7285555-B2 | 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1684763-A1 | 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES AS ANTICANCER AGENT | Wyeth Holdings Corporation (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005030218-A1 | 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES AS ANTICANCER AGENT | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050065167-A1 | 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255157-A1 | 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents | ABCC1, TUBB3, ABCB1 | PKM 2958/4885RIPK1 3663/4885L3MBTL1 412/4885 |
| US-20050065167-A1 | 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents | ABCC1, TUBB3, ABCB1 | PKM 2958/4885RIPK1 3663/4885L3MBTL1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.